Truist raised the firm’s price target on Insmed (INSM) to $139 from $126 and keeps a Buy rating on the shares. The firm is positive on the stock and updating its model following approval of BRINSUPRI ...

PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced ...

Brensocatib (Brinsupri; Insmed) gains FDA approval as the first treatment for bronchiectasis, offering hope to patients with ...

With a landmark U.S. approval  Tuesday, Insmed is making waves with a new class of drug that’s also the first to be green lit ...

The FDA granted approval to brensocatib for treating adults and children aged at least 12 years with non-cystic fibrosis ...

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under ...

Gain key insights from Insmed's Q2 2025 earnings call, including strong ARIKAYCE growth, brensocatib launch prep, pipeline progress, and robust ...

For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration (FDA) has ...

Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permane ...

Brinsupri is a first-in-class DPP1 inhibitor that has been found to inhibit activation of neutrophil enzymes that drive chronic airway inflammation in non-cystic fibrosis bronchiectasis.

The US Food and Drug Administration approved New Jersey, USA-based Insmed’s (Nasdaq: INSM) fibrosis bronchiectasis (NCFB), a ...